These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26439969)

  • 1. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
    Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
    J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
    Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
    Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G; Tauhid S; Dupuy SL; Tummala S; Khalid F; Healy BC; Bakshi R
    J Neurol; 2016 Mar; 263(3):531-8. PubMed ID: 26754005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor.
    Chen M; Valenzuela RM; Dhib-Jalbut S
    J Neurol Sci; 2003 Nov; 215(1-2):37-44. PubMed ID: 14568126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
    J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
    Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
    Blanco Y; Moral EA; Costa M; Gómez-Choco M; Torres-Peraza JF; Alonso-Magdalena L; Alberch J; Jaraquemada D; Arbizu T; Graus F; Saiz A
    Neurosci Lett; 2006 Oct; 406(3):270-5. PubMed ID: 16934924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate in multiple sclerosis: a review.
    Ruggieri M; Avolio C; Livrea P; Trojano M
    CNS Drug Rev; 2007; 13(2):178-91. PubMed ID: 17627671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
    Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
    Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.
    Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G
    Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
    Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C
    BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
    Karussis D; Teitelbaum D; Sicsic C; Brenner T;
    J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
    Izquierdo G; García-Agua Soler N; Rus M; García-Ruiz AJ
    Brain Behav; 2015 Jun; 5(6):e00337. PubMed ID: 26085963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
    Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
    Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
    Ziemssen T; Calabrese P; Penner IK; Apfel R
    J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers.
    Neuhaus O; Köhler W; Then Bergh F; Kristoferitsch W; Faiss J; Rosenkranz T; Reske D; Patejdl R; Hartung HP; Zettl UK
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33800033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.